Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non–small cell lung cancer  by Yokomise, Hiroyasu et al.
G
S
I
c
c
H
Teneral Thoracic
urgerynduction chemoradiotherapy (carboplatin-taxane and
oncurrent 50-Gy radiation) for bulky cN2, N3 non–small
ell lung cancer
iroyasu Yokomise, MD, Masashi Gotoh, MD, Taku Okamoto, MD, Yasumichi Yamamoto, MD, Shinya Ishikawa, MD,
akashi Nakashima, MD, Daiki Masuya, MD, Dage Liu, MD, and Cheng-long Huang, MD
O
p
c
M
c
m
o
c
t
w
R
m
r
T
b
r
(
s
c
g
C
a
p
r
T
s
c
c
G
TSFrom the Second Department of Surgery,
Faculty of Medicine, Kagawa University,
Miki-cho, Japan.
Received for publication Aug 6, 2006; re-
visions received Nov 21, 2006; accepted for
publication Dec 12, 2006.
Address for reprints: Hiroyasu Yokomise,
MD, Second Department of Surgery, Fac-
ulty of Medicine, Kagawa University,
Miki-cho, Kita-gun, Kagawa, 761-0793, Ja-
pan (E-mail: yokomise@kms.ac.jp).
J Thorac Cardiovasc Surg 2007;133:1179-85
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgery
Dr Yokomise (back row, second from left) and
his staffC
doi:10.1016/j.jtcvs.2006.12.039
Tbjective: To improve the prognosis of cN2, N3 non–small cell lung cancer, we
erformed induction chemoradiotherapy (carboplatin-taxane chemotherapy and
oncurrent 50-Gy radiation) followed by surgery.
ethods: Patients with pathologically proven non–small cell lung cancer with bulky
N2, N3 disease were enrolled. Forty-one patients underwent an operation after che-
oradiotherapy from January 2000 to April 2006. Either carboplatin-paclitaxel (n 19)
r carboplatin-docetaxel (n  22) chemotherapy was randomly used. Two cycles of
hemotherapy were performed with concurrent radiation (50 Gy). In all cases, conven-
ional radiological reevaluations were performed; in the latest 21 cases, reevaluations
ith positron-emission tomography with fludeoxyglucose F 18 were also performed.
esults: In all 41 cases, complete resections were performed, with no operative
ortality. The histologically complete response rate, major response rate, and minor
esponse rate were 17.1% (7/41), 56.1% (23/41), and 26.8% (11/41), respectively.
he 5-year overall survival was 52.7%. There were no differences in survival
etween taxane groups. Both the complete response and the major response groups
evealed a significantly better 5-year survivals than the minor response group
85.7%, P  .044, 52.4%, P  .01). Even with persistent N2 disease, the 5-year
urvival in the major response group (66%) was promising. With the combination of
onventional computed tomography and positron-emission tomography with fludeoxy-
lucose F 18 for reevaluation, eligible patients could be selected for this protocol.
onclusion: Surgery after chemoradiotherapy (carboplatin-taxane and 50-Gy radi-
tion) for bulky cN2, N3 non–small cell lung cancer can be safely performed with
romising results. Even with persistent N2 disease, the survival in the major
esponse group was promising.
he treatment of patients with bulky cN2, N3 non–small cell lung cancer
(NSCLC) remains controversial and challenging. At present, few patients
with bulky N2, N3 disease undergo surgery before induction therapy. Several
tudies have suggested that preoperative chemotherapy1,2 or chemoradiotherapy3-6
an improve the survival of patients with such N2 NSCLC. The optimal protocol for
hemotherapy or the recommended radiation dose, however, is still undefined.
isplatin-etoposide (EP) therapy has commonly been used for the induction therapy
he Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 5 1179
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G
TSf advanced NSCLC.3,4 A recent study reported that carbo-
latin-paclitaxel (CP) therapy demonstrated an equivalent
urvival to EP therapy but with an overall benefit in mor-
idity and quality of life.7,8 Regarding taxane, the selection
f paclitaxel or docetaxel is still undetermined.9 Concerning
he radiation dose, the most commonly used dose for induc-
ion therapy may be 40 to 45 Gy.3-6 Recent studies have
eported that high-dose radiation promotes a high patholog-
cally complete response rate with a favorable survival.10
The accurate selection of optimal candidates for surgery
fter induction chemoradiotherapy is therefore extremely
mportant. Recently, a pathologically complete response
nd pN0 have been reported to be accurate predictors of a
etter outcome.3,11 In this study, we attempted to evaluate
he efficacy of each taxane with a moderately high radiation
Abbreviations and Acronyms
CT  computed tomography
CD  carboplatin-docetaxel
CP  carboplatin-paclitaxel
EP  cisplatin-etoposide
FDG-PET positron emission tomography with
fludeoxyglucose F 18
NSCLC  non–small cell lung cancer
SUV  standardized uptake valueFigure 1. Representative computed tomographic fin
180 The Journal of Thoracic and Cardiovascular Surgery ● Maose (50 Gy) in induction chemoradiotherapy for bulky-N2,
3 NSCLC to determine useful predictors of better survival.
atients and Methods
his prospective, randomized trial was carried out on selected
atients with bulky cN2, N3 NSCLC from January 2000 to April
006. This study was approved by the institutional review board of
he Kagawa University. The patient eligibility criteria were estab-
ished as follows: (1) The patient had pathologically proven
SCLC. (2) There was no previous therapy. (3) Performance
tatus was 0 to 2. (4) Patient was younger than 75 years. (5)
ediastinal lymph nodes were seen with a short-axis diameter
ore than 2 cm on chest computed tomography (CT), considered
o be bulky cN2 metastasis. The CT findings of representative
ases are shown in Figure 1. Although mediastinoscopy may be the
tandard criterion for an evaluation of N2 disease,12,13 we did not
outinely perform it. Because most of our cases were suspected of
aving invasive and extranodal expansion, a safe biopsy without
ny complications appeared to be a debatable procedure. Further-
ore, because the sensitivity of mediastinoscopy is reported to be
round 80%,12,13 20% of the patients with possible N2 disease can
ose the chance to receive potentially valuable treatment. (6) No
istant metastasis were revealed by chest CT, abdominal CT, brain
T or magnetic resonance imaging, and bone scan. Positron emis-
ion tomography with fludeoxyglucose F 18 (FDG-PET) was
ntroduced in our institution in June 2004; since then, the assess-
ent of distant metastasis has been done by FDG-PET. (7) The
atient was able to tolerate chemoradiotherapy in terms of com-
lete blood count, chemistry profile, and creatinine clearance. (8)dings of bulky cN2 mediastinal lymph nodes.
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G
TSardiac function was normal. Normal cardiac function includes
ormal single and master-double electrocardiograms and ejection
raction greater than 50%. (9) The predicted postoperative forced
xpiratory volume in 1 second was more than 800 mL. (10) The
atient’s informed consent had been obtained.
herapeutic Schedule
hemotherapy was conducted during week 1, and concurrent
adiotherapy with 30 Gy (2 Gy/d, 5 d/wk) was conducted during
eeks 1, 2, and 3. After a 1-week withdrawal period, chemother-
py was carried out during week 5, and concurrent radiotherapy
ith 20 Gy was carried out during weeks 5 and 6. The therapies
ere discontinued for 1 to 4 weeks, depending on patient condi-
ion, and a reevaluation was carried out on the basis of chest CT,
bdominal CT, brain CT or magnetic resonance imaging, and bone
can 2 to 3 weeks after the end of radiation therapy. The latest 21
atients were also evaluated preoperatively by FGD-PET and then
eevaluated after induction therapy. A routine reevaluation was
one according to the criteria of response evaluation criteria in
olid tumors.14,15 A complete resolution of all targets was defined
s complete response, and at least a 30% reduction (quantified as
he longest diameter) in the tumor size was defined as partial
esponse. A reevaluation by FDG-PET was done under the re-
ently recommended criteria.16,17 The images were evaluated both
ualitatively and quantitatively. The qualitative evaluations before
nd after induction therapy were done by a visual inspection. The
ntensity of FDG accumulation after induction therapy lower than
ediastinal structures was classified as a better response and a
reater accumulation was classified as a poor response. A quanti-
ative evaluation was done according to the standardized uptake
alue (SUV) decreasing rate. A SUV decreasing rate of more than
0% after induction therapy was classified as a better response and
ess than 70% as a poor response. Both the visual inspection and
UV decreasing rate were used as a reevaluation index, and double-
ositive cases were defined as good responses in the FDG-PET
tudy. A reference SUV may be variable even in the same patient,
specially in different patients. We therefore performed a qualita-
ive evaluation by visual inspection to compensate for the weak-
ess of a reference SUV. Regarding the SUV decreasing rate, our
adiologists report that the average of the decreasing rate in re-
ponders after induction therapy (74.1  10.1) is significantly
igher than in nonresponders (55.5  14.8, P  .003).17 As a
esult, we used the 70% threshold.
After reevaluation, operations were performed on all patients
xcept those with progressive disease. In all cases, bronchial
tumps were covered with intercostal muscle after a pneumonec-
omy or with a pericardial fat pad after a lobectomy. One thoracic
urgeon (Yokomise H) performed all the operations.
hemotherapy
he patients were randomly assigned to a CP arm or a carboplatin-
ocetaxel (CD) arm. The patients in the CP arm received carbo-
latin (area under the curve 6 mg/[mL · min], 30-minute intra-
enous infusion) on day 1 and paclitaxel (180 mg/m2, 3-hour
ntravenous infusion) on day 1. Premedication for the prevention
f hypersensitivity reactions included dexamethasone, diphenhy-
ramine, and cimetidine. Patients in the CD arm received carbo-
latin (area under the curve 6 mg/[mL · min], 30-minute intra- R
The Journal of Thoracicenous infusion) on day 1 and docetaxel (60 mg/m2, 3-hour
ntravenous infusion) on day 1.
adiotherapy
n area including the hilum of the lung and mediastinum with a
.5-cm margin from the periphery of the primary lesion was
rradiated with 2 Gy/d. In the patients with cervical N3 disease, the
upraclavicular area was also irradiated. The patients received
rradiation 5 times weekly, with 2 nonirradiation days set up.
tatistical Analysis
tatistical analysis of the data was carried out with the StatView
.5J program (SAS Institute, Inc, Cary, NC). The survival curves
ere estimated by the method of Kaplan and Meier.18 The differ-
nces in the groups were evaluated with the log–rank test.
esults
rom January 2000 to April 2006, a total of 41 patients were
nrolled: 19 patients in the CP arm and 22 patients in the
D arm. The characteristics of the patients are shown in
able 1. The median age was 61.9 years (37-75 years). The
roup comprised 35 men and 6 women. Thirty-one patients
ad stage IIIA disease, and 10 had stage IIIB disease. Four
ad right ipsilateral cervical N3, and all N3 cases were
iagnosed by aspiration cytologic examination. The cN2
tatuses are shown in Table 1. Thirty patients had single-
tation N2 disease and 11 had multistation N2 disease. In
ddition, 21 had squamous cell carcinoma, 19 had adeno-
arcinoma, and 1 had large cell carcinoma.
All 41 patients completed the protocol. Induction therapy
as generally well tolerated, and no serious complications
r deaths related to induction therapy occurred. The grade 4
ide effects observed were limited to granulocytopenia in 11
atients (26.8%); thrombocytopenia was seen in 0, renal
ysfunction in 0, and abdominal symptoms in 0. Six patients
ad radiation pneumonitis (Radiation Therapy Oncology
roup grade 3-4),19 and all recovered from it with the
dministration of corticosteroids. The details of morbidity
uring induction therapy and after operation are shown in
able 2.
The overall response rate of conventional reevaluation
as 78% (4 cases of complete response and 28 cases of
artial response), and stable disease was identified in 9
ases. A good response on FDG-PET was observed in 75%
f cases. Because there was no progressive disease, surgery
as performed in all 41 patients according to the protocol.
n all cases, a complete resection could be done. Lobecto-
ies or bilobectomies were performed in 28 patients; pneu-
onectomies were performed in 13 patients. In 4 patients
ith N3 disease (ipsilateral cervical node involvement), an
dditional cervical lymph node dissection was performed.
he pathologic effect of induction therapy was evaluated
ccording to General Rule for Clinical and Pathological
ecord of Lung Cancer, 6th edition.20 A pathologically
and Cardiovascular Surgery ● Volume 133, Number 5 1181
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1
G
TSomplete response (complete cancer cell death) was achieved
n 7 cases (17.1%). A major response (fewer than one third
f cancer cells viable) was achieved in 23 cases (56.1%). A
ABLE 1. Patient characteristics
o. of patients 41
ge (y, median and range) 61.9 (37–75)
ex (No.)
Male 35
Female 6
istologic type (No.)
Squamous cell carcinoma 21
Adenocarcinoma 19
Large cell carcinoma 1
NM staging (No.)
IIIB
T4 N3 M0 1 (T4: vertebra; N3:
ipsilateral cervical)
T4 N2 M0 6 (T4: vertebra, 2; PA: 2;
carina: 1; PM1: 1)
T2 N3 M0 3 (ipsilateral cervical N3: 3)
IIIA
T3 N2 M0 4
T2 N2 M0 15
T1 N2 M0 12
rigin (No.)
Right upper lobe 16
Left upper lobe 9
Right lower lobe 9
Left lower lobe 5
Right middle lobe 2
N2 status (No.)
Single nodal station
#4 17
#7 7
#5 5
#3 1
Multiple nodal stations
#4 and #7 5
#4 and #5 2
#2 and #7, #5 and #7, #3 and
#5, #1-#4
1
peration performed (No.)
Lobectomy, bilobectomy 28
Pneumonectomy 13
Right 9
Left 4
omplex operation (No.)
Combined resection of azygos
vein
3
Vertebral body and rib resection 2
Combined resection of superior
vena cava
1
A, Pulmonary artery; PM1, metastasis to the same lobe as the primary
umor.inor response (more than two thirds cancer cells viable) c
182 The Journal of Thoracic and Cardiovascular Surgery ● Maas observed in 11 cases (26.8%). All patients with N3 had
ight side cases, and 3 of 4 cases of cervical N3 achieved
ownstaging (2 to N2 and 1 to N0). There was no mortality
r major morbidity after surgery. No bronchial fistula was
een after either lobectomy or pneumonectomy.
The median observation time was 2.63 years. The 5-year
verall survival was 52.7% (Figure 2). No significant dif-
erence in survival was observed between the CP group and
he CD group (P  .92; Figure 3). Six of the 7 patients with
athologically complete response are still alive. One died of
stroke 3 months after the operation. Fourteen of 23 pa-
ients with a major response are alive. Six of 11 patients
ith a minor response died early, and there were no cases of
ong-term survival (Figure 4). The 5-year survivals for
athologically complete response, major effect, and minor
ffect were 85.7%, 52.4%, and 0%, respectively. Both the
omplete response group and the major response group
evealed significantly better 5-year survivals than the minor
esponse group (P  .044 and P  .01). Twenty-four of 41
atients had persistent pN2 diseases (58.5%) after surgery.
even had residual pN1 diseases, and 10 had pN0. The
athologic response after induction therapy was identical to
hat reported previously.3,21 We did not perform mediasti-
oscopy to evaluate N2 disease for the reasons mentioned
reviously, and our cases thus may have included some
alse-positive N2 (actually N0 or N1) disease. We identified
4 definitive pN2 cases after surgery. The overall 5-year
urvival of these 24 cases was 48%. Among them, the 14 in
he major pathologic response group had a 5-year survival
f 66%. On the other hand, the 10 in the minor response
roup showed an extremely poor survival. A significant
ifference was seen between these two groups (P  .0003;
igure 5). Among the pN2 cases, good responses for both
onventional and FDG-PET reevaluation were seen in 8
atients, all with a major response. The impact of multista-
ion cN2 was evaluated. The survival of patients with mul-
istation cN2 (2-year survival 15%) was significantly poorer
han that of patients with single-station cN2 (5-year survival
4%, P .0001). Two of 4 patients with ipsilateral right N3
ave been alive for more than 5 years. There was no
ifference in overall survival between patients with lobec-
omies and pneumonectomies. For both operative modali-
ies, no major morbidity or mortality was observed.
iscussion
s chemoradiotherapy became the standard treatment for
dvanced nonresectable stage IIIA and IIIB NSCLC,22-24
everal multidisciplinary treatments were tried for poten-
ially resectable diseases.3-5 Recently, a large clinical trial
Intergroup protocol 0139) finished, and both the short-term
nd long-term results have been reported.11,25 Albain and
olleagues11,25 reported the 5-year survival for patients un-
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G
TSergoing surgery after EP chemotherapy and 45-Gy radia-
ion to be 27%, with pN0 predicting better survival.
Our study reveals that induction chemoradiotherapy fol-
owed by a complete surgical resection for advanced bulky
N2, N3 NSCLC can been performed with an acceptable
orbidity and a promising survival. Our multidisciplinary
reatments consist of taxane (paclitaxel or docetaxel) and
arboplatin chemotherapy, concurrent 50-Gy radiation, and
urgery. Recent studies report that the effect of taxane-
arboplatin chemotherapy is equivalent to that of the EP
egimen, which has been the criterion standard for chemo-
adiotherapy for advanced NSCLC.7,8 Furthermore, lower
oxicity has been reported for taxane-carboplatin therapy
elative to EP therapy.7 In our study, grade 4 toxicities
ccurred at a relatively low rate. Other grade 3 toxicities
ere commonly seen, but no particular treatments were
equired. As a result, the quality of life of the patients was
aintained during our treatment. No severe perioperative
ABLE 2. Morbidity during induction therapy and operatio
0
oxicity
Leukopenia 1 (2%) 1
Granulocytopenia 1 (2%) 1
Thrombocytopenia 30 (73%) 5
Anemia 16 (39%) 16
Gastrointestinal tract 19 (46%) 11
Vomiting 31 (76%) 5
Renal dysfunction 34 (83%) 3
adiation pneumonitis RTOG grade 3-4
epsis
ronchial fistula
ll data represent numbers and percentages of patients. RTOG, RadiationFigure 2. Overall survival for all 41 cases. T
The Journal of Thoracicdverse events were documented. The side effects were
quivalent for paclitaxel and docetaxel.
The most commonly used dose of radiation for induction
herapy may be 40 to 45 Gy.3-6 Recent studies report that
igh-dose radiation may result in a high pathologically
omplete response rate with a favorable survival.10 Some of
ur patients seemed to require radiation before surgery, and
igh morbidity and mortality rates after pneumonectomy
ave been reported for chemoradiotherapy with 60-Gy con-
urrent radiation.26 For these reasons, we selected 50 Gy as
he concurrent radiation dose. In all 41 cases, definitive
urgery (lobectomy and pneumonectomy) could be per-
ormed after concurrent 50-Gy chemoradiation with accept-
ble morbidity and no mortality. No bronchial stump fistu-
as occurred after surgery. The reinforcement of the
ronchial stump with a muscular flap or pericardial fat pad
ay have contributed to these positive results.
th maximum toxicities during concurrent chemoradiation
Grade of toxicity
2 3 4 Affected
7 (17%) 26 (63%) 6 (15%)
9 (22%) 19 (46%) 11 (27%)
) 4 (10%) 2 (5%) 0 (0%)
) 7 (17%) 2 (5%) 0 (0%)
) 9 (22%) 2 (5%) 0 (0%)
) 5 (12%) 0 (0%) 0 (0%)
2 (5%) 2 (5%) 0 (0%)
6 (15%)
1 (2%)
0 (0%)
apy Oncology Group.
igure 3. Overall survival according to chemotherapy protocol.n wi
1
(2%)
(2%)
(12%
(39%
(27%
(12%
(7%)XL, Paclitaxel; TXT, docetaxel.
and Cardiovascular Surgery ● Volume 133, Number 5 1183
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1
G
TSThe overall survival of the patients remains promising.
he pathologically complete response rate is identical to
hose previously reported for studies in which pN2 was
roved by mediastinoscopy.3,6 The survival for the com-
lete response group is also encouraging. In most studies of
nduction therapy for cN2 NSCLC, mediastinoscopy has
een applied for the confirmation of mediastinal nodes as a
riterion standard.4,6,25 For commonly accepted cN2 with a
hort-axis diameter of 1 to 2 cm on chest CT, we usually
erform mediastinoscopy. For previously mentioned rea-
ons, however, we do not perform mediastinoscopy on
andidates for this multidisciplinary therapy. Our bulky N2
isease was far advanced, and it appeared to be invasive
ith extranodal expansion. The morbidity and mortality of
ediastinoscopy are low and acceptable.12,13 Our policy
tresses that preoperative screening must be safe, without
ny morbidity or mortality. Furthermore, possible candi-
ates for this therapy may also lose the chance to receive
otentially valuable alternative treatments for these highly
orbid diseases.
Indeed, N0 or N1 disease could have been included in
ur study because of the omission of mediastinoscopy;
owever, 24 patients (58.5%) had residual N2 disease after
nduction therapy. For such a small number of patients, the
verall survival of this category is encouraging. In the major
esponse group with residual N2 disease, the survival was
uperior to that reported before for those with N1 disease.27
n the other hand, the survival of the minor response group
as extremely poor.
In the Intergroup 0139 study,11,25 the treatment-related
eath rate after pneumonectomy was extremely high (25.9%,
4/52). Albain and colleagues11,25 concluded that their ap-
roach might not be optimal if a pneumonectomy was
eeded. A pneumonectomy may, however, be inevitable for
hose with advanced N2 disease. In our study, survivals
ere identical for patients who underwent lobectomy and
Figure 4. Overall survival according to pathologic response.hose who underwent pneumonectomy. t
184 The Journal of Thoracic and Cardiovascular Surgery ● MaThe selection of optimal candidates for surgery after
nduction chemoradiotherapy is considered to be extremely
mportant. Recently, a pathologically complete response
nd pN0 have been reported to be accurate predictors of
etter outcome.3,11 Tremendous efforts, including remedi-
stinoscopy, have been tried.12 The pathologically complete
esponse group, however, may comprise only 10% to 20%
f all patients who receive induction therapy. Grunenwald
nd Albain suggest that surgery is an efficient salvage
reatment for patients with N3 NSCLC with viable residual
isease after chemoradiotherapy.9,28 Our series may be akin
o N3 disease. We showed that the status of the mediastinal
odes as major pathologic response versus minor response
ight be good a predictor of a better survival. The experi-
nce of our N3 series is limited, but 2 of 4 patients have
een alive more than 5 years. Considering the surgical
rocedure, the patient with right ipsilateral N3 disease may
e a good candidate for our induction therapy. In our study,
he patients with pN2 disease who showed major pathologic
esponse had a promising 5-year survival (66%). In addi-
ion, with the combination of a conventional CT study and
DG-PET study, we may have selected optimal surgical
andidates after induction therapy without invasive proce-
ures. Both the visual and the functional reevaluations may
herefore be effective. It may be difficult to demonstrate the
rade of the pathologic response of mediastinal nodes by
emediastinoscopy. The survival of patients with multista-
ion cN2 was extremely poor. That subset may thus not be
andidates for this induction therapy.
In conclusion, surgery after induction therapy (taxane
nd carboplatin with 50-Gy radiation) for bulky cN2, N3
SCLC could be performed with both an acceptable mor-
idity and promising results. Even with residual N2 disease,
igure 5. Overall survival of patients with persistent pN2 disease
ccording to pathologic response.he survival was favorable in the major response group. To
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G
TSredict better survival after induction therapy, the combina-
ion of conventional CT and FDG-PET reevaluations is
seful.
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